Correct Answer: C. Enhance fibrin degradation
Tissue plasminogen activator (tPA) is a fibrinolytic agent that works by converting plasminogen to plasmin, which then degrades fibrin—the structural protein of blood clots. Unlike anticoagulants (which prevent clot formation) or antiplatelet agents (which inhibit platelet function), tPA is a thrombolytic that actively dissolves existing clots. The mechanism is highly specific: tPA binds to fibrin within the clot and activates plasminogen preferentially at the clot surface, generating plasmin that cleaves fibrin into fibrin degradation products (FDPs). This fibrinolytic action is the basis for its use in acute myocardial infarction, acute ischemic stroke, and pulmonary embolism in Indian clinical practice. The key discriminator is that tPA enhances fibrin degradation (fibrinolysis), not inhibition of clot formation or platelet function. According to KD Tripathi and Harrison, tPA's selectivity for fibrin-bound plasminogen makes it superior to older agents like streptokinase, reducing systemic fibrinolysis and bleeding risk—a critical advantage in Indian hospitals with resource constraints and high-risk populations.
Why the other options are wrong
A. Inhibit extrinsic pathway — This is wrong because tPA does not act on the coagulation cascade at all. Inhibition of the extrinsic pathway is the mechanism of warfarin (vitamin K antagonist) or direct factor Xa inhibitors (apixaban, rivaroxaban). tPA is a fibrinolytic, not an anticoagulant. This is an NBE trap confusing anticoagulation with fibrinolysis. B. Inhibits platelet aggregation — This is wrong because tPA has no antiplatelet action. Platelet aggregation inhibition is the mechanism of aspirin (COX inhibitor), clopidogrel (P2Y12 antagonist), or ticagrelor. tPA works downstream of platelets, directly on fibrin. This trap confuses antiplatelet agents with thrombolytics. D. Inhibit clot formation — This is wrong because tPA does not prevent clot formation—it dissolves existing clots. Inhibition of clot formation is the mechanism of anticoagulants like heparin (factor IIa and Xa inhibitor) or dabigatran (direct thrombin inhibitor). tPA is pro-fibrinolytic, not anti-thrombotic. This is the most common trap: confusing prevention with dissolution.
High-Yield Facts
- tPA mechanism: Converts plasminogen → plasmin → fibrin degradation (fibrinolysis), not anticoagulation.
- Fibrin selectivity: tPA preferentially activates plasminogen at the clot surface, reducing systemic bleeding compared to streptokinase.
- Clinical use in India: tPA is DOC for acute MI (within 12 hours) and acute ischemic stroke (within 4.5 hours) per STEMI and stroke guidelines.
- Fibrin degradation products (FDPs): Elevated FDPs and D-dimer confirm active fibrinolysis; used to monitor tPA efficacy.
- Contraindication: Active bleeding, recent surgery, intracranial hemorrhage—tPA increases bleeding risk due to systemic plasmin generation.
- Comparison: tPA (fibrin-selective) > streptokinase (non-selective) in reducing myocardial rupture and reinfarction in Indian acute MI cohorts.
Mnemonics
tPA = Thrombus-Plasmin Activator tPA → Plasminogen → Plasmin → Fibrin breakdown. Remember: tPA activates plasmin, which degrades fibrin. Not about preventing clots, but dissolving them. Fibrinolytic vs Anticoagulant (FAST rule) Fibrinolytic (tPA, streptokinase) = dissolves clots. Anticoagulant (heparin, warfarin) = prevents clots. Separate mechanisms. Test: tPA works on existing clots; anticoagulants prevent new ones.
NBE Trap
NBE pairs tPA with "inhibit clot formation" to trap students who confuse thrombolytics (dissolve clots) with anticoagulants (prevent clots). The cognitive error: thinking "stops clotting" = "inhibits clot formation" rather than "dissolves existing clots."
Clinical Pearl
In Indian acute MI wards, tPA (alteplase) is preferred over streptokinase in eligible patients because its fibrin selectivity reduces systemic bleeding and reinfarction—critical in settings with limited ICU monitoring. A patient with acute STEMI given tPA will show rising D-dimer and FDPs within 30 minutes, confirming active fibrinolysis and clot dissolution.
_Reference: KD Tripathi Pharmacology Ch. 28 (Fibrinolytic Agents); Harrison Ch. 112 (Antithrombotic Therapy)_